From our friends at Nautilus:
Pfizer, one of the drug companies that has successfully brought a COVID-19 vaccine to market, is now considering charging more for that vaccine in the future.
As CBS News reported, a top executive for the company suggested to investors that COVID-19 vaccine pricing could increase post-pandemic. As the report about the Pfizer vaccine noted, “The suggestion raises questions about whether a drug, developed at the behest of the federal government to respond to a global crisis, could turn a profit for one company.”
Carter Lewis Gould, a senior analyst for Biopharma Equity Research at Barclays, asked about the possibility during a Barclays-hosted virtual global healthcare conference held the week of March 8. Gould, in referencing comments made by Pfizer executives during the summer of 2020, asked whether Pfizer might pursue “higher pricing” as “we move from a pandemic to an endemic phase,” according to an edited transcript of the conversation.
Read the rest of the Nautilus story here.
